Prognostic value of immunohistochemistry for p53 in primary soft-tissue sarcomas: A multivariate analysis of five antibodies

Journal of Cancer Research and Clinical Oncology

Volumn 123, Issue 9, 1997, Pages 502-508

  Würl, Peter ^a   Taubert, Helge ^a   Meye, Axel ^a   Berger, Dieter ^a   Lautenschläger, Christine ^a   Holzhausen, Hans Jürgen ^a   Schmidt, Hannelore ^a   Kalthoff, Holger ^b   Rath, Friedrich Wilhelm ^a   Dralle, Henning ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Immunohistochemistry; P53; Prognosis; Soft tissue sarcoma

Indexed keywords

PROTEIN P53;

ADOLESCENT; ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SOFT TISSUE SARCOMA;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; MULTIVARIATE ANALYSIS; PROGNOSIS; SARCOMA; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 9844229070     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320050095     Document Type: Article

References (52)

1. Bass IO, Mulder JWR, Offerhaus JA, Vogelstein B, Hamilton SR (1994) An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172:5-12
2. Banks L, Matlashewski G, Crawford L (1986) Isolation of human p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 59:529-534
3. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Rejthar A, Kovarik J. Lane DP (1990) Patterns of expression of the p53 tumour suppressor in human breast tissue and tumours in situ and in vivo. Int J Cancer 46:839-844
4. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, Kovarik J, Midgley CA, Gannon JV, Lane DP (1991) Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6:1699-1703
5. Bell SM, Scott N, Cross D, Sagar P, Lewis FA, Blair GA, Taylor GL, Dixon MF, Quirke P (1993) Prognostic value of p53 overexpression and c-Ki-ras mutations in colorectal cancer. Gastroenterology 104:57-64
6. Bosari S, Viale G (1995) The clinical significance of p53 aberrations in human tumours. Virchows Arch 427:229-241
7. Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM, Marechal V, Chen J, Brennan MF, Levine JL (1994) Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54:794-799
8. Dolcetti R, Doglioni C, Maestro R, Gasparotto D, Barzan L, Pastore A, Romanelli M, Bolocchi M (1992) p53 over-expression is an early event in the development of human squamous-cell carcinoma of the larynx: genetic and prognostic implications. Int J Cancer 52:178-182
9. Drobnjak M, Latres E, Pollack D, Karpeh M, Dudas M, Woodruff JM, Brennan MF, Cardon-Cardo C (1994) Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki-67 in adult soft tissue sarcomas. J Nail Cancer Inst 86:549-554
10. Ebina M, Steinberg SM, Mulshine JL, Linnoila RI (1994) Relationship of p53 overexpression and upregulation of proliferating cell nuclear antigen with the clinical course of non-small cell luna cancer. Cancer Res 54:2496-2503
11. Elledge RM, Clark GM, Fuqua SA, Yu YY, Allred DC (1994) p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res 54:3752-3757
12. Enzinger FM, Weiss SW (1995) soft tissue tumors, 3rd edn. Mosby, Strews, pp 1-16, 131-164, 269-292, 351-380, 431-466, 491-510, 539-578, 889-928
13. Gottlieb MG, Oren M (1996) p53 in growth control and neoplasie. Biochim Biophys Acta 1287:77-102
14. Hall PA, Lane DP (1994) p53 in tumour pathology: can we trust immunohistochemistry? - revised! J Pathol 172:1-4
15. Harris C (1996) p53 tumor suppressor gene: from the basic research laboratory to the clinic-an abridged historical perspective. Carcinogenesis 17:1187-1198
16. Home GM, Anderson JJ, Tiniakos DG, McIntosh GG, Thomas MD, Angus B, Henry JA, Lennard TWJ, Horne CHW (1996) p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry. Br J Cancer 73:29-35
17. Isola J, Visakorpi T, Holli K, Kallioniemi OP (1992) Association of overexpression of tumor supressor gene protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84:1109-1114
18. Kalthoff H, Schmiegel W, Roeder C, Kasche D, Schmidt A, Lauer G, Thiele HG, Honold G, Pantel K, Riethmüller G, Scherer E, Maurer J, Maacke H, Deppert W (1993) p53 and K-ras alterations in pancreatic epithelial cell lesions. Oncogene 8:289-298
19. Kawai A, Noguchi M, Beppu Y, Yokoyama R, Mukai K, Hirohashi S, Inoue H, Fukuma H (1994) Nuclear immunoreaction of p53 protein in soft tissue sarcomas. Cancer 73:2499-2505
20. Russie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, Pavletich NP (1996) Structure of the MDM2 oncoproteine bound to the p53 tumor suppressor transactivation domain. Science 274:948-953
21. Lambkin HA, Mothershill CM, Kelehan P (1994) Variations in immunohistochemical detection of p53 protein overexpression in cervical tumours with different antibodies and methods of detection. J Pathol 172:13-18
22. Latres E, Drobnjak M, Pollack D, Oliva MR, Ramos M, Karpeh M, Woodruff JM, Cordon-Cardo C (1994) Chromosome 17 abnormalities and p53 mutation in adult soft tissue sarcomas. Am J Pathol 145:345-354
23. Leach FS, Tokino T, Metzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B (1993) p53 mutation and mdm2 amplification in human soft tissue sarcomas. Cancer Res 53:2231-2234
24. Legros Y, Lacabanne V, d'Agay MF, Larsen CJ, Pla M, Soussi T (1993) Production of human p53 specific monoclonal antibodies and their use in immunohistochemical studies of tumor cells. Bull Cancer 80:102-110
25. Ling J, Chen J, Elenbaas B, Levine AJ (1994) Several Hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm2 and the adenovirus 5 E1B 55-kD-protein. Genes Dev 8:1235-1246
26. McLaren R, Kuzu I, Dunnill M, Harris A, Lane D, Gatter KC (1992) The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 66:735-738
27. Midgley CA, Fisher CJ, Bartek J, Vojtesek B, Lane D, Barnes DM (1992) Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. J Cell Sci 101:183-189
28. Mousses S, McAuley L, Bell RS, Kandel R, Andrulis IL (1996) Molecular and immunohistochemical identification of p53 alterations in bone and soft tissue sarcomas. Mod Pathol 9:1-6
29. Niemann TH, Raab SS, Lenel JC, Rodgers JR, Robinson RA (1995) p53 protein overexpression in smooth muscle tumors of the uterus. Hum Pathol 26:375-379
30. Ohuc M, Tomita N, Monden T, Fujita M, Fukunaga M, Takami KA (1994) Frequent alteration of p53 gene in carcinoma in adenoma of colon. Cancer Res 54:4798-4804
31. Oshiro Y, Fukuda T, Tsuneyoshi M (1994) Fibrosarcoma versus fibromatoses and cellular nodular fasciitis. A comparative study of their proliverative activity using proliferating cell nuclear antigen, DNA flow cytometry, and p53. Am J Surg Pathol 18:712-719
32. Patterson H, Gill S, Fisher C, Law MG, Jayatilake H, Fletcher CDM, Thomas M, Grimer R, Gusterson BA, Cooper CS (1994) Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas. Br J Cancer 69:1052-1058
33. Reid AH, Tsai MS, Venzon DJ, Wright CF, Lack EE, O'Leary TJ (1996) MDM2 amplification, p53 mutation, and accumulation of the p53 gene product in malignant fibrous histiocytoma. Diagn Mol Pathol 5:65-73
34. Said J, Barrera R, Shintaku IP, Nakamura H, Koeffler HP (1992) Immunohistochemical analysis of p53 expression in malignant lymphomas. Am J Pathol 141:1343-1348
35. Segers K, Backhovens H, Singh SK, de Voecht J, Ramael M, van Broeckhoven C, van Marck E (1995) Immunoreactivity for p53 and mdm2 and the detection of mutations in human malignant mesothelioma. Virchows Arch 427:431-436
36. Stephen CW, Lane DP (1992) Mutant conformation of p53. Precise epitope mapping using filamentous phage epitope library. J Mol Biol 225:577-583
37. Stephen CW, Helminen P, Lane DP (1995) Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insight into antibody-peptide interactions. J Mol Biol 248:58-78
38. Stürzbecher HW, Addison C, Jenkins JR (1988) Characterization of mutant p53-hsp72/73 protein-protein complexes by transient expression in monkey COS cells. Mol Cell Biol 8:3740-3747
39. Taubert H, Würl P, Meye A, Berger D, Thamm B, Neumann K, Hinze R, Schmidt H, Rath FW (1995) Molecular and immunohistochemical p53 status in liposarcoma and malignant fibrous histiocytoma. Cancer 76:1187-1196
40. Taubert H, Meye A, Würl P (1996) Prognosis is correlated with p53 mutation type for soft tissue sarcoma patients. Cancer Res 56:4134-4136
41. Toffoli G, Doglioni C, Cernigoi C, Frustaci S, Perin T, Canal B, Boiocchi M (1994) p53 overexpression in human soft tissue sarcomas: relation to biological aggressiveness. Ann Oncol 5:167-172
42. Tominaga O, Hamelin R, Trouvat V, Salmon RJ, Lesec G, Thomas G, Remvikos Y (1993) Frequently elevated content of immunochemically defined wild-type p53 protein in colorectal adenomas. Oncogene 8:2553-2558
43. Unger T, Nau MM, Segal S, Minna JD (1992) p53: a trans-dominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J 11:1383-1390
44. Unnik JAM van, Coindre JM, Contesso G, Albus-Lutter CE, Schiodt T, Garcia-Miralles T (1988) Grading of soft tissue sarcomas. In: Ryan JR, Baker LO (eds) Experience of the EORTC soft tissue and bone sarcoma treatment. Kluwer Academic, Dordrecht, pp 7-13
45. Vojtesek B, Bartek J, Midgley CA, Lane DP (1992) An immunochemical analysis of the human nuclear phosphoprotein p53: new monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 151:237-244
46. Vojtesek B, Dolezalova H, Lauerova L, Svitakova M, Havlis P, Kovarik J, Midgley CA, Lane DP (1995) Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein. Oncogene 10:389-393
47. Wadayama B, Toguchida J, Yamaguchi T, Sasaki MS, Kotoura Y, Yamamuro T (1993) p53 expression and its relationship to DNA alterations in hone and soft tissue sarcomas. Br J Cancer 68:1134-1139
48. Wang DY, Xiang YY, Tanaka M, Li XR, Li JL, Shen Q, Sugimura H, Kino I (1994) High prevalence of p53 overexpression in patients with oesophageal cancer in Linxian, China and its relationship to progression and prognosis. Cancer 74:3089-3096
49. Watanahe R, Tomita Y, Nishiyama T, Tanikawa T, Sato S (1994) Correlation of p53 protein expression in urothelial transitional cell cancers with malignant potential and patient survival. Int J Urol 1:43-48
50. Würl P, Taubert H, Bache M, Kroll J, Meye A, Siermann A, Holzhausen H-J, Hinze R, Schmidt H, Rath F-W (1996) Frequent occurrence of p53 mutations in rhabdo- and leiomyosarcoma, but not in fibrosarcoma and malignant neural tumors. Int J Cancer 69:317-323
51. Wynford-Thomas D (1992) p53 in tumour pathology: can we trust immunocytochemistry? J Pathol 166:329-330
52. Yang P, Hirose T, Hasegawa T, Seki K, Sano T, Hizawa K (1995) Prognostic implication of the p53 protein and K-67 antigen: immunohistochemistry in malignant fibrous histiocytoma. Cancer 76:618-625